Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Front Immunol ; 12: 794638, 2021.
Article in English | MEDLINE | ID: covidwho-1731769

ABSTRACT

CCR5 plays a central role in infectious disease, host defense, and cancer progression, thereby making it an ideal target for therapeutic development. Notably, CCR5 is the major HIV entry co-receptor, where its surface density correlates with HIV plasma viremia. The level of CCR5 receptor occupancy (RO) achieved by a CCR5-targeting therapeutic is therefore a critical predictor of its efficacy. However, current methods to measure CCR5 RO lack sensitivity, resulting in high background and overcalculation. Here, we report on two independent, flow cytometric methods of calculating CCR5 RO using the anti-CCR5 antibody, Leronlimab. We show that both methods led to comparable CCR5 RO values, with low background on untreated CCR5+CD4+ T cells and sensitive measurements of occupancy on both blood and tissue-resident CD4+ T cells that correlated longitudinally with plasma concentrations in Leronlimab-treated macaques. Using these assays, we found that Leronlimab stabilized cell surface CCR5, leading to an increase in the levels of circulating and tissue-resident CCR5+CD4+ T cells in vivo in Leronlimab-treated macaques. Weekly Leronlimab treatment in a chronically SIV-infected macaque led to increased CCR5+CD4+ T cells levels and fully suppressed plasma viremia, both concomitant with full CCR5 RO on peripheral blood CD4+ T cells, demonstrating that CCR5+CD4+ T cells were protected from viral replication by Leronlimab binding. Finally, we extended these results to Leronlimab-treated humans and found that weekly 700 mg Leronlimab led to complete CCR5 RO on peripheral blood CD4+ T cells and a statistically significant increase in CCR5+CD4+ T cells in peripheral blood. Collectively, these results establish two RO calculation methods for longitudinal monitoring of anti-CCR5 therapeutic antibody blockade efficacy in both macaques and humans, demonstrate that CCR5+CD4+ T cell levels temporarily increase with Leronlimab treatment, and facilitate future detailed investigations into the immunological impacts of CCR5 inhibition in multiple pathophysiological processes.


Subject(s)
Antibodies, Monoclonal, Humanized/therapeutic use , CD4-Positive T-Lymphocytes/immunology , COVID-19/drug therapy , Flow Cytometry/methods , HIV Antibodies/therapeutic use , HIV Infections/drug therapy , HIV-1/physiology , Receptors, CCR5/metabolism , SARS-CoV-2/physiology , Simian Acquired Immunodeficiency Syndrome/drug therapy , Simian Immunodeficiency Virus/physiology , Animals , CD4 Lymphocyte Count , Female , Humans , Primates , Protein Binding , Receptors, CCR5/immunology , Treatment Outcome
2.
EuropePMC; 2020.
Preprint in English | EuropePMC | ID: ppcovidwho-315186

ABSTRACT

Background: Our study aimed to investigate the prognostic value of a novel inflammatory index, systemic immune-inflammation index (SII), with the clinical outcomes of patients infected with coronavirus disease 2019 (COVID-19).Methods We evaluated a cohort study of COVID-19 patients (18–95 years old) in Tongji Hospital of Huazhong University of Science and Technology from January 28th 2020 to February 29th 2020. The enrolled patients were divided into two groups (including low-SII group and high-SII group) according to the cut-off point which is analyzed by receiver operating characteristic (ROC) curve. Univariate and multivariate COX regression analysis were performed to identify the factors associated with the outcomes of patients with COVID-19 infection. The primary and secondary outcome were in-hospital mortality and the development of acute respiratory distress syndrome (ARDS), respectively.Results A number of 326 adult patients (43.87% males, 61.22 ± 0.86 years) were enrolled in the final analyses. There were 147 cases (45.09%) died in hospital and 116 patients (35.58%) developed ARDS. ROC curve analysis indicated that the SII had a greater prediction accuracy in predicting the in-hospital mortality (area under the curve [AUC] = 0.789, sensitivity = 69.90%, specificity = 70.80%) and the development of ARDS (AUC = 0.736, sensitivity = 67.80%, specificity = 71.10%). Kaplan-Meier analysis revealed that patients in high-SII group had a greater risk of adverse clinical outcomes (all P  < 0.001). The multivariate Cox regression analysis indicated that elevated SII was found as the risk predictor of in-hospital mortality (hazard ratio [HR] = 2.839, 95% confidence interval [CI] = 1.116–7.222, P  = 0.028) and the developed ARDS (HR = 6.832, 95%CI = 2.583–18.074, P  < 0.001). Additional significant independent predictor for adverse outcomes was the lymphocyte proportion. What’s more, it suggests that the invasive mechanical ventilation performed in the early stage of the disease progression may be beneficial for patients.Conclusion SII, a novel biomarker, might be a remarkable prognostic indicator to assess the in-hospital mortality and the development of ARDS in patients with COVID-19 and help for clinical risk assessment.

3.
Zhongguo Zhen Jiu ; 41(10): 1109-12, 2021 Oct 12.
Article in Chinese | MEDLINE | ID: covidwho-1464064

ABSTRACT

OBJECTIVE: To observe the effect of moxibustion combined with Daiwenjiu plaster on mental disorder and self rating symptoms in close contacts of coronavirus disease 2019 (COVID-19) during quarantine. METHODS: A total of 240 close contacts of COVID-19 were randomized into an observation group (120 cases, 18 cases dropped off) and a control group (120 cases, 58 cases dropped off). Conventional observation was adopted in the control group. Moxibustion combined with Daiwenjiu plaster was given in the observation group, moxibustion was applied at Zusanli (ST 36), Hegu (LI 4) and Shenque (CV 8), 10 min each acupoint, once a day; Daiwenjiu plaster was applied at Dazhui (GV 14) and Feishu (BL 13) for 3 to 6 h each time, once every 2 days, the treatment was required for 2 weeks. Before and after treatment and in the follow-up of 2 weeks after treatment, self-reporting questionnaire 20 (SRQ-20), self-rating anxiety scale (SAS) scores and self rating symptoms were evaluated in the two groups. RESULTS: In the follow-up, SRQ-20 score was decreased compared before treatment (P<0.01), SAS score was decreased compared before and after treatment (P<0.01, P<0.05) in the observation group. After treatment and in the follow-up, SRQ-20 scores in the observation group were lower than those in the control group (P<0.05, P<0.01). After treatment, the case proportion of fatigue in the observation group was higher than that in the control group (P<0.05). In the follow-up, the case proportion of tension was lower than that in the control group (P<0.05). CONCLUSION: Moxibustion combined with Daiwenjiu plaster can effectively improve the mental disorder in close contacts of COVID-19.


Subject(s)
COVID-19 , Mental Disorders , Moxibustion , Acupuncture Points , Humans , SARS-CoV-2
5.
SciFinder; 2020.
Preprint | SciFinder | ID: ppcovidwho-4421

ABSTRACT

A review. The 2019 novel coronavirus (2019-nCoV) was discovered in Wuhan in 2019, and the outbreak has received great attention from the World Health Organization (WHO), because it concerns people′s life safety and health as well as the overall situation of economic and social development. The CPC central committee and the state council have made prevention and control of the epidemic a top priority. This article reviews the development of coronaviruses and novel coronaviruses, the characteristics of novel coronaviruses, the prevention of vaccines, the application of therapeutic drugs, and the development of therapeutic drugs. Focusing on the development of the new coronavirus and the epidemic situation, implementing the principle of prevention and strengthening the management of major outbreaks, the authors put forward some suggestions on strengthening the construction of China′s public health system, keeping innovation and strengthening the basic research of scientific development and application.

6.
CAplus; 2020.
Preprint | CAplus | ID: ppcovidwho-2063

ABSTRACT

A review. Aromatic Chinese herbs has been used to prevent plague since ancient times, and traditional Chinese medicine has unique advantages in the prevention and treatment of epidemic disease. Corona virus disease 2019 (COVID-19) is rampant, and the National Health Commission of the People's Republic of China issued guidelines recommends treatment plans with integrated traditional Chinese and Western medicine. According to the traditional Chinese medicine treatment plan in the National COVID-19 Diagnosis and Treatment Plan (Trial Seventh Edition) of the National Health Commission, Chinese patent medicines or prescriptions containing more aromatic Chinese herbs are selected for prevention and treatment during the period of medical observation, clin. treatment and recovery of confirmed patients. Some local health committees or traditional Chinese medicine administrations also recommend a variety of other ways to use aromatic traditional Chinese herbs (external fumigation, moxibustion, wearing sachet, etc.) to prevent and cure COVID-19. The efficacy of "fragrance repels filth and reinforces vital qi" of aromatic Chinese herbs plays a pos. role in the prevention and treatment of COVID-19. It has become a consensus to use aromatic Chinese herbs to interfere with the occurrence and development of COVID-19. The unique properties, chem. composition and action mechanism of aromatic Chinese herbs are worthy of extensive and in-depth exptl. and clin. research, which can provide reference for the follow-utreatment of novel coronavirus and the development of corresponding drugs. Based on the theory of traditional Chinese medicine, this paper discusses the role of aromatic Chinese herbs in the prevention and treatment of COVID-19, and speculates the possible mechanism of its function, in order to provide a basis for attaching importance to the prevention and treatment of COVID-19.

7.
Chin Herb Med ; 12(4): 347-348, 2020 Oct.
Article in English | MEDLINE | ID: covidwho-753787
8.
Chin. Trad. Herbal Drugs ; 9(51): 2273-2282, 20200512.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-684116

ABSTRACT

Coronavirus disease 2019 (COVID-19) has become a major global epidemic, and traditional Chinese medicine (TCM) has played an important role in the prevention and control of major epidemics. Taking Shufeng Jiedu Capsule as an example, this paper summarized the ideas and research practice of TCM in early intervention, blocking disease progression, improving symptoms, anti-inflammation and immunoregulation, suppressing "cytokine storm", syndrome differentiation and playing the advantages of compatibility based on the understanding of COVID-19. The idea of establishing a scientific model for the research and development of new drugs of TCM was put forward.

9.
Chin. Trad. Herbal Drugs ; 11(51): 2967-2976, 20200612.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-682204

ABSTRACT

Objective: To explore the network regulation mechanism of Tanreqing Capsule (TRQC) on the treatment of coronavirus disease 2019 (COVID-19). Methods: Potential targets of the 19 major constituents in TRQC were predicted by the Swiss Target Prediction server and TCMSP database. Gene ontology (GO) function enrichment and pathway analysis of the targets were analyzed by Omicsbean analytic system and String 10 database. Finally, Cytoscape 3.6.1 software was used to construct the network pharmacology map. Results: A total of 19 compounds affected 68 pathways such as IL-17 signaling pathway, T cell receptor signaling pathway, arachidonic acid metabolism, cAMP signaling pathway, PI3K-Akt signaling pathway, influenza A, etc, by acting on 163 related targets, which associated with anti-inflammation, immune regulation, antipyresis, eliminating phlegm, relieving cough and asthma, analgesia, antibacterial and antiviral, and sedation. The network of "compound-target-pathway-pharmacological action-efficacy" was also constructed. Conclusion: The major constituents in TRQC, including scutellarin, baicalin, oroxylin-7-O-glucuronide, chrysin-7-O-glucuronide, forsythin, forsythiaside E, forsythiaside D, chlorogenic acid, caffeic acid, isochlorogenic acid A, ursodeoxycholic acid and chenodeoxycholic acid, may interfere with efficacy-related biological processes associated with antipyresis, eliminating phlegm and removing toxin by acting on key protein like TNF, EGFR, NOS3, PTGS2, IL2, GABBR1, MAPK14, ADRB2, REN, VCAM1, ACHE, PTPRC, etc.

10.
Zhongguo Zhen Jiu ; 40(6): 571-5, 2020 Jun 12.
Article in Chinese | MEDLINE | ID: covidwho-602103

ABSTRACT

Acupuncture and moxibustion has a wealth of experience in the prevention and control of epidemic disease since ancient times, which was used for all kinds of acute infectious diseases in modern times and its efficacy has been clearly and reliably reported. This article proposes the theoretical feasibility and reliability of acupuncture and moxibustion interventional prevention and treatment by discussing the recognition of coronavirus disease 2019 (COVID-19) from the perspective of acupuncture and moxibustion. The unique "acupuncture and moxibustion program" for COVID-19 is presented including treatment in different stages, selecting acupoints by distinguishing meridians, applying needle technique by various methods. The article also proposes a new understanding of acupuncture and moxibustion at related acupoints on the surface of the body that can directly affect the "moyuan" to treat the disease.


Subject(s)
Acupuncture Therapy , Coronavirus Infections , Moxibustion , Pandemics , Pneumonia, Viral , Betacoronavirus , COVID-19 , Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Humans , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , Reproducibility of Results , SARS-CoV-2
11.
Chin Herb Med ; 12(3): 207-213, 2020 Jul.
Article in English | MEDLINE | ID: covidwho-459353

ABSTRACT

Members of the China-ASEAN Joint Laboratory for International Cooperation in Traditional Medicine Research used the video conference platform to exchange and discuss the advantages of traditional medicine through the form of score exchange and report, and research and develop the amount and issues of the therapeutic COVID-19 products of concern. This paper mainly reviews the achievements of the implementation of the epidemic prevention and control plan, advances of scientific basic studies on SARS-CoV-2, analysis and screening of potential targets and pathways of antiviral compounds based on network pharmacology and development of antiviral food dual-use products. The authors believe that the declaration of the (10 + 3) special meeting of national leaders on epidemic prevention and control should raise the medical and pharmaceutical issues of common concern. It is the responsibility of our joint laboratory members to accelerate the development of traditional medicine research and industry. Also the authors believe that this exchange will certainly promote the development of the cause of cooperation.

12.
Eur Urol Focus ; 6(5): 1124-1129, 2020 Sep 15.
Article in English | MEDLINE | ID: covidwho-437089

ABSTRACT

BACKGROUND: Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), involves multiple organs. Testicular involvement is largely unknown. OBJECTIVE: To determine the pathological changes and whether SARS-CoV-2 can be detected in the testes of deceased COVID-19 patients. DESIGN, SETTING, AND PARTICIPANTS: Postmortem examination of the testes from 12 COVID-19 patients was performed using light and electron microscopy, and immunohistochemistry for lymphocytic and histiocytic markers. Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the virus in testicular tissue. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Seminiferous tubular injury was assessed as none, mild, moderate, or severe according to the extent of tubular damage. Leydig cells in the interstitium were counted in ten 400× microscopy fields. RESULTS AND LIMITATIONS: Microscopically, Sertoli cells showed swelling, vacuolation and cytoplasmic rarefaction, detachment from tubular basement membranes, and loss and sloughing into lumens of the intratubular cell mass. Two, five, and four of 11 cases showed mild, moderate, and severe injury, respectively. The mean number of Leydig cells in COVID-19 testes was significantly lower than in the control group (2.2 vs 7.8, p < 0.001). In the interstitium there was edema and mild inflammatory infiltrates composed of T lymphocytes and histiocytes. Transmission EM did not identify viral particles in three cases. RT-PCR detected the virus in one of 12 cases. CONCLUSIONS: Testes from COVID-19 patients exhibited significant seminiferous tubular injury, reduced Leydig cells, and mild lymphocytic inflammation. We found no evidence of SARS-CoV-2 virus in the testes in the majority (90%) of the cases by RT-PCR, and in none by electron microscopy. These findings can provide evidence-based guidance for sperm donation and inform management strategies to mitigate the risk of testicular injury during the COVID-19 disease course. PATIENT SUMMARY: We examined the testes of deceased COVID-19 patients. We found significant damage to the testicular parenchyma. However, virus was not detected in testes in the majority of cases.


Subject(s)
Coronavirus Infections/pathology , Pneumonia, Viral/pathology , Seminiferous Tubules/pathology , Testis/pathology , Adult , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme 2 , Betacoronavirus , COVID-19 , Cell Count , Coronavirus Infections/metabolism , Coronavirus Infections/physiopathology , Humans , Inflammation , Leydig Cells/pathology , Leydig Cells/ultrastructure , Male , Microscopy, Electron , Middle Aged , Pandemics , Peptidyl-Dipeptidase A/metabolism , Pneumonia, Viral/metabolism , Pneumonia, Viral/physiopathology , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2 , Seminiferous Tubules/ultrastructure , Sertoli Cells/pathology , Sertoli Cells/ultrastructure , Spermatogenesis/physiology , Testis/metabolism , Testis/ultrastructure , Testis/virology
13.
Chin. Trad. Herbal Drugs ; 6(51): 1361-1374, 20200328.
Article in Chinese | WHO COVID, ELSEVIER | ID: covidwho-380567

ABSTRACT

In the first 20 years of the new century, two times of coronavirus “visiting” China has become a public health emergency, which has attracted great attention at home and abroad. At the critical time of epidemic prevention and control in SARS-CoV-2 infection, the excellent achievements of traditional Chinese medicine (TCM) show the advantages and contributions of TCM. In view of the complexity of the symptoms of patients with coronavirus infection, the diversity of organ and tissue damage and functional damage or failure, how to adapt to the needs of clinical prevention and treatment is not only a problem of modern medicine, but also a problem of TCM. In this review article, the authors combed the research of TCM prescription and single medicine after understanding the cause of coronavirus infection and pathogenicity and multiple organ dysfunction and failure caused by coronavirus. Based on the emphasis on the TCM scientific research and application, the TCM therapeutic effect on SARS-CoV-2 infection is discussed. The framework of new drug research and development based on possible “target” is proposed, and we put forward the ideas for researching new TCM products through the expanding molecular mechanism of infection.

14.
Zhongguo Zhen Jiu ; 40(5): 457-61, 2020 May 12.
Article in Chinese | MEDLINE | ID: covidwho-245498

ABSTRACT

On the base of the idea of traditional Chinese medicine as "disease prevention", the mode and the protocol of the moxibustion intervention for the group under quarantine after close contact with coronavirus disease 2019 (COVID-19) were explored. The group under quarantine after close contact with COVID-19 was taken as the subjects. By the non-contact physician-patient communication network platform co-developed by China Association of Acupuncture-Moxibustion, Hunan Provincial Association of Acupuncture-Moxibustion, Data Center of China Academy of Chinese Medical Sciences and Yuge Medicine Company, an exploratory randomized controlled trial was designed. A total of 100 cases were included and randomized into a moxibustion group and a conventional intervention group, 50 cases in each one. In the moxibustion group, moxibustion intervention was used. In the conventional intervention group, the conventional observation was adopted without moxibusiton intervention applied. The outcomes included the symptoms changes, e.g. anxiety, emotional disturbance, fatigue, headache and diarrhea, as well as whether quarantine release and the case confirmed or not, etc. The results were evaluated before intervention, in 14 days of intervention and 2 weeks after intervention separately. In this research, on the base of internet plus technology and with the internet communication platform adopted, through mobile phone WeChat App, it was to implement the subject screen, the random allocation and the instruction of moxibustion intervention as well as the quality control of patient's diary and data collection. It is anticipated that the significance and the implementation mode of moxibustion intervention can be assessed preliminarily for the group under quarantine after close contact with COVID-19.


Subject(s)
Acupuncture Therapy/methods , Betacoronavirus , Coronavirus Infections/therapy , Moxibustion , Pneumonia, Viral/therapy , COVID-19 , China , Humans , Pandemics , Quarantine , SARS-CoV-2
15.
Chin Herb Med ; 12(2): 97-103, 2020 Apr.
Article in English | MEDLINE | ID: covidwho-65818

ABSTRACT

Since the outbreak of the new coronavirus epidemic, novel coronavirus has infected nearly 100,000 people in more than 110 countries. How to face this new coronavirus epidemic outbreak is an important issue. Basic reproduction number (R0) is an important parameter in epidemiology; The basic reproduction number of an infection can be thought of as the expected number of cases directly generated by one case in a population where all individuals are susceptible to infection. Epidemiology dynamics is a mathematical model based on a susceptibility-infection-recovery epidemic model. Researchers analyzed the epidemiological benefits of different transmission rates for the establishment of effective strategy in prevention and control strategies for epidemic infectious diseases. In this review, the early use of TCM for light and ordinary patients, can rapidly improve symptoms, shorten hospitalization days and reduce severe cases transformed from light and normal. Many TCM formulas and products have wide application in treating infectious and non-infectious diseases. The TCM theoretical system of treating epidemic diseases with TCM and the treatment scheme of integrated Chinese and Western medicine have proved their effectiveness in clinical practice. TCM can cure COVID-19 pneumonia, and also shows that the role of TCM in blocking the progress of COVID-19 pneumonia.

SELECTION OF CITATIONS
SEARCH DETAIL